Record annual revenue and positive Adjusted EBITDA were achieved, driven by strong core services growth and operational improvements. Data revenue declined due to a non-recurring large transaction, but the customer base expanded and margins improved. Investments position the company for future grow…
Record annual revenue and positive adjusted EBITDA were achieved, driven by strong core services and operational efficiencies. Investments in data, AI, and Corellia position the business for future growth, though data revenue remains variable and external funding for Corellia is pending.Based on Ch…
CSBR (Champions Oncology, Inc.) is set to announce its Q4'25 results on July 27, after the market closes. The earnings are expected to be disclosed at 4:00 PM ET (8:00 PM UTC).For Q4'25, revenue estimate is 12.89 million USD with EPS (earnings per share) anticipated at (0.05) USD. Learn more detail…
Life sciences companies continue to operate in an environment supported by growing investment in biomedical research, increasing demand for precision medicine and continued drug discovery activity across the pharmaceutical and biotechnology industries. Against this backdrop, Champions Oncology, Inc…
